IP Library Granted Patent US 9,333,364
Granted Patent B2
US 9,333,364 · App. 12/829,183 · Granted May 10, 2016

Methods and systems for heart failure treatments using ultrasound and leadless implantable devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,333,364
App. No.
12/829,183
Granted
May 10, 2016
Kind
B2
Abstract

The present invention relies on a controller-transmitter device to deliver ultrasound energy into cardiac tissue in order to directly improve cardiac function and/or to energize one or more implanted receiver-stimulator devices that transduce the ultrasound energy to electrical energy to perform excitatory and/or non-excitatory treatments for heart failure. The acoustic energy can be applied as a single burst or as multiple bursts.

Claims (17)

1. A system for heart failure therapy comprising:

one or more acoustic receiver-stimulators having an electrode assembly wherein at least one of the electrodes is adapted to be implanted in direct contact with cardiac tissue at one or more heart locations selected to provide a preferred pattern of activation or mechanical contraction; and

an acoustic controller-transmitter comprising a housing, at least one physiological sensor disposed on an outer surface of the housing configured to sense the patient's electrogram, and a control circuitry configured to utilize the electrogram to control therapeutic functions; wherein the acoustic controller-transmitter is adapted to transmit acoustic energy into a patient's body and which provides both energy and signal information to the receiver-stimulator sufficient to stimulate the heart and

wherein the receiver-stimulator further comprises an acoustic receiver which receives the acoustic energy and generates alternating current, converter circuitry which produces a direct current or waveform from the alternating current to stimulate the cardiac tissue, and electrodes adapted to deliver the direct current or waveform to the cardiac tissue and wherein the control circuitry is configured to control the acoustic energy transmission based on the electrogram sensed by the physiological sensor to simultaneously or selectively to a) activate the receiver-stimulator to deliver excitatory therapy, b) activate the receiver-stimulator to deliver non-excitatory therapy, or c) provide direct sonication of the cardiac tissue.

2. A system as in claim 1 , wherein the implantable receiver-stimulator is adapted to be placed and secured at a location in or on the left ventricle.

3. A system as in claim 1 ,

wherein the controller-transmitter is configured to be implanted subcutaneously at a location allowing sonication of tissue in both ventricles and activation of one or more implanted receiver-stimulator.

4. A system for the delivery of therapy to a patient's heart, comprising:

an acoustic controller-transmitter comprising a housing and at least one physiological sensor disposed on an outer surface of the housing configured to sense one or more of the patient's physiologic parameters, and circuitry configured to utilize the detected physiologic parameters to activate the receiver-stimulator or to provide direct sonication in order to adjust therapeutic functions selected from one or more of the following preconfigured functions:

(a) ultrasound sonication of heart tissue to improve cardiac function, (b) ultrasound sonication of heart tissue to prevent deterioration of cardiac function, (c) leadless pacing to improve cardiac function, (d) leadless pacing to prevent deterioration of cardiac function, (e) leadless cardiac contractility modulation to improve cardiac function, and (f) leadless cardiac contractility modulation to prevent deterioration of cardiac function;

wherein the cardiac function is one or more of contractility, vasodilation, tissue perfusion, or aortic pressure.

5. A system as in claim 4 , wherein leadless pacing or leadless cardiac contractility modulation therapy is delivered by one or more acoustic receiver-stimulators having an electrode assembly adapted to be implanted in direct contact with the heart and activated by the said acoustic controller-transmitter,

wherein the control-transmitter and receiver-stimulator are adapted to transmit and receive acoustic energy which provides both energy and signal information to the receiver-stimulator,

wherein the receiver-stimulator comprises an acoustic receiver which receives acoustic energy and generates alternating current, means for converting the alternating current to a direct current or waveform to electrodes adapted to deliver the direct current or waveform to myocardial tissue,

wherein the controller-transmitter directs acoustic energy to the receiver-stimulator

wherein the implantable receiver-stimulator is adapted to be placed and secured at a location sufficient to prevent and/or treat heart failure.

6. A system as in claim 4 , wherein the controller-transmitter is implantable in the patient's body in a subcutaneous region and directs acoustic energy to the heart.

Assignments (1)
SECURITY INTEREST Recorded Jul 1, 2022
From: EBR SYSTEMS, INC.
To: RUNWAY GROWTH FINANCE CORP.
Reel/Frame 060560/0639 →